Robo Medical Secures Series A+ Funding from Hangzhou Guoshun Jianheng to Accelerate Launch of EndoFaster Digestive Endoscopy Surgical Robot
ROBO Medical
Medical Robot Developer
VCBeat has exclusively learned that Shenzhen ROBO Medical Technology Co., Ltd. (“ROBO Medical”), a leading player in the global field of digestive endoscopic surgical robots, has securedHangzhou Guoshun Jianheng Venture Capital Partnership (LimitedPartnership) (hereinafter referred to as “Hangzhou Guoshun Jianheng”)Series A+ financing,MedBio CapitalServing as the exclusive financial advisor. This round of financing will support the market promotion of the company’s EndoFaster digestive endoscopy surgical robot, as well as the research and development and market launch of multiple innovative medical products.
Since its establishment in 2015, ROBO Medical has been dedicated to innovation in the medical technology sector, achieving remarkable results particularly in the field of digestive endoscopic surgical robots. It is understood thatROBO Medical’s EndoFaster, a robotic system for digestive endoscopic surgery, completed its first-in-human registration clinical trials at six clinical centers across China, including Qilu Hospital of Shandong University and Shanghai Changhai Hospital, in August 2023. In November 2023, it was included in the National Innovative Medical Device Green Channel. Market approval is expected by the end of 2024.
Natural orifice surgical robots are currently a key focus and challenge in the research and development of surgical robotics. ROBO Medical’s EndoFaster digestive endoscopic surgical robot system is one of the world’s leading natural orifice surgical robots, offering advantages such as high control precision, high flexibility, and a low incidence of complications. The system features a 2.5-mm-diameter flexible robotic arm attached to the side of the digestive endoscope, providing physicians with a “third hand” within confined luminal spaces.
With EndoFaster entering clinical use, digestive endoscopic surgery has officially entered the era of surgical robots. Many industry experts state that the EndoFaster digestive endoscopic surgical robot system not only has broad clinical application prospects in the domestic market but is also expected to expand into the international market in the future. With the market launch and application of EndoFaster and the introduction of new types of consumables based on its platform, it is believed that surgical robot technology can truly achieve the universalization and standardization of digestive endoscopic surgery, laying a solid foundation for expanding the indications of digestive endoscopic surgery from the mucosal layer to the serosal layer.
Meanwhile, ROBO Medical’s newly developed product——The second-generation dual-channel natural orifice surgical robot, the EndoDreams system, has recently completed multiple in vivo animal experiments and is scheduled to enter type testing in the fourth quarter of 2024.In the future, this system will not only coverCorresponding Surgical Procedures for Gastrointestinal Surgery, and will also be expanded toUrology, Obstetrics and Gynecologyand many other fields.
Related Reading: